Table 2.
Soluble PRR, renin, prorenin, AGT, and TGF-β1 in plasma and urine
| Variables | Total participants | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | Type 2 diabetes | P value | Control | Type 2 diabetes | P value | Control | Type 2 diabetes | P value | |
| Plasma | |||||||||
| sPRR (ng/mL) | 16.5 (15.8–17) | 19.2 (17–21)* | 0.001 | 18 (16.5–19) | 17 (16–20) | 0.87 | 15 (14.8–16) † | 20 (18–22)‡ |
†0.05 ‡0.001 |
| Renin activity (ng Ang-I /mL/h) | 3.2 (2.7–3.8) | 12 (10–14)* | 0.001 | 3.5 (2.5–4.5) | 9.8 (6.4–13.3)† ‡ ** |
†0.001 ‡0.001 **0.05 |
3.0 (2.3–3.7) | 13 (11–15.6)† ‡ |
†0.001 ‡0.001 |
| Urine | |||||||||
| sPRR/uCr (ng/mg) | 1.6 (1.3–1.8) | 0.8 (0.6–1)* | 0.001 | 1.8 (1.4–2.4) | 0.6 (0.4–0.8)† ‡ |
†0.001 ‡0.05 |
1.3 (1–1.7) | 1.0 (0.75–1.3) † | †0.001 |
| Renin activity (ng Ang-I /mL/h) | 27 (21–33) | 99 (77–120)* | 0.001 | 27 (16.5–37.4) | 125 (82–168)† ‡ ** |
†0.001 ‡0.001 **0.05 |
27 (20–34) | 84 (60–108)† ‡ |
†0.001 ‡0.001 |
| Prorenin/uCr (ng/g) | 141 (109–173) | 302 (232–371)* | 0.01 | 128 (91–165) | 362 (215–508)† ‡ |
†0.01 ‡0.05 |
153 (103–204) | 273 (199–348)† | †0.01 |
| AGT/uCr (μg/g) | 16 (13–19) | 25 (17–32)* | 0.02 | 15 (11–20) | 30 (17–42)† ‡ |
†0.05 ‡0.05 |
16 (12–20) | 21 (11–20) | 0.52 |
| TGF-β1/uCr (pg/mg) | 18 (14–22) | 31 (24–38)* | 0.001 | 16 (11–21) | 33 (20–45)† | †0.05 | 19 (13–25) | 31 (23–39)† | †0.05 |
Data are shown as mean (95% confident intervals). *Different from total participants’ control; †Different from men control; ‡Different from women control. **Different from women with type 2 diabetes